Open AccessPeramivir and laninamivir susceptibility of circulating influenza A and B viruses
Author(s) -
Leang SookKwan,
Kwok Simon,
Sullivan Sheena G.,
MaurerStroh Sebastian,
Kelso Anne,
Barr Ian G.,
Hurt Aeron C.
Publication year - 2014
Publication title -
influenza and other respiratory viruses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.743
H-Index - 57
eISSN - 1750-2659
pISSN - 1750-2640
DOI - 10.1111/irv.12187
Subject(s) - zanamivir , virology , neuraminidase , neuraminidase inhibitor , influenza a virus , virus , biology , chemistry , microbiology and biotechnology , medicine , covid-19 , infectious disease (medical specialty) , disease , pathology
Influenza viruses collected from regions of A sia, A frica and O ceania between 2009 and 2012 were tested for their susceptibility to two new neuraminidase inhibitors, peramivir and laninamivir. All viruses tested had normal laninamivir inhibition. However, 3·2% (19/599) of A(H1N1)pdm09 viruses had highly reduced peramivir inhibition (due to H275Y NA mutation) and <1% (6/1238) of influenza B viruses had reduced or highly reduced peramivir inhibition, with single occurrence of variants containing I221T, A245T, K360E, A395E, D432G and a combined G145R+Y142H mutation. These data demonstrate that despite an increase in H275Y variants in 2011, there was no marked change in the frequency of peramivir‐ or laninamivir‐resistant variants following the market release of the drugs in J apan in 2010.